ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 0221

A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network

Grant Cannon1, Beth Wallace2, Deana Lazaro3, Pascale Schwab4, Paul Monach5, Ankoor Shah6, Gail Kerr7, Andreas Reimold8, Joshua Baker9, Gary Kunkel10, Katherine Wysham11, Liron Caplan12, John Richards13, Aleksander Lenert14, Andrew Jones15, Ted Mikuls16, Maria I. ("Maio") Danila17, Bryant England16, Brian Sauer18, Jorge Rojas19 and Isaac Smith20, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3VA New York Harbor Healthcare system, Short Hills, NJ, 4VA Portland and Oregon Health & Science University, Portland, OR, 5VA Boston Healthcare System, Boston, MA, 6Duke University, Durham, NC, 7Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 8Dallas VA Medical Center, Dallas, TX, 9University of Pennsylvania, Philadelphia, PA, 10University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12Rocky Mountain Regional VAMC, Aurora, CO, 13Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 14University of Iowa, Iowa City, IA, 15VA Saint Louis and Washington University, Saint Louis, 16University of Nebraska Medical Center, Omaha, NE, 17University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 18Salt Lake City VA/University of Utah, Salt Lake City, UT, 19VA Puget Sound Health Care System, Seattle, WA, 20Duke University Hospital, Durham, NC

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Measurement Instrument, Quality Indicators, quality of care, rheumatoid arthritis

Session Information

Date: Sunday, October 26, 2025

Title: (0210–0232) Measures & Measurement of Healthcare Quality Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of clinical and epidemiologic research in RA. The Veterans Affairs RA (VARA) registry is a prospective cohort study of Veterans with RA that is active at 16 VA Medical Centers. A VARA goal is to systematically collect and document eight DAM components for participants at each in-person clinic visit (Table1). A multimodal intervention was initiated to enhance DAMs collection. This report details preliminary results following three months of implementation of this planned 12-month program.

Methods: This intervention involved three phases: 1) baseline; 2) development: and 3) implementation (Table 1). Key activities included qualitative interviews with site investigators to confirm availability of electronic health record (EHR) tools for DAM collection, provision of additional EHR tools if needed, development of monthly just-in-time lists of VARA participant appointments, and monthly provider-specific feedback on DAMs collection performance and comparison to VARA registry overall performance. Verification and retrieval of documented DAM components in the EHR was accomplished through data extraction of note text form the VA Corporate Data Warehouse. Performance at each encounter, by provider and by VARA site over the 3-month implementation phase was compared to baseline performance using chi square testing.

Results: Between March 2024 through March 2025, 3,576 in-person rheumatology clinic visits occurred in 1,436 RA patients enrolled in VARA who were seen by 135 unique providers. The distribution of these visits and basic demographic information on these patients during the baseline, development, and implementation phases are listed (Table 1). Compared to baseline values, there was a significant increase in the documentation of individual DAM components, combined DAM components, and composite DAMs during the implementation phase with increases ranging from 5.8% to 10.4% (Table 2). Analyses limited to the 44 providers completing ≥5 clinical notes during both the baseline and implementation phases demonstrated an increase in the number of providers successfully documenting DAMs in >50% of encounters (Table 3). A separate analysis of DAMs collection by all providers at each VARA site also showed improvement in the number of VARA sites successfully documenting DAMs (Table 3).

Conclusion: This multimodal intervention increased DAM collection and documentation in clinical notes, expanded the number of providers consistently collecting DAMs, and enhanced the performance at VARA registry sites during an initial 3-month intervention phase. Ongoing monitoring will determine if additional performance improvement occurs through sustained intervention over a 12-month follow-up. This work demonstrates that collaborative actions in a multi-center registry can improve both the quantity and quality of high-yield clinical data collected to facilitate patient care and research. These methods may be applied in additional clinical settings to improve real-world collection of DAMs.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. Cannon: None; B. Wallace: None; D. Lazaro: None; P. Schwab: None; P. Monach: Boehringer-Ingelheim, 2; A. Shah: Adtium Bio, 2, Cabaletta Bio, 5, Horizon Therapeuatics, 5, Mitsubishi, 2; G. Kerr: Amgen, 2, Bristol-Myers Squibb(BMS), 2, CSL-Behring, 2, Janssen, 2, Novartis, 2, Pfizer, 2, Sanofi, 2, UCB, 2; A. Reimold: None; J. Baker: Amgen, 5; G. Kunkel: None; K. Wysham: None; L. Caplan: None; J. Richards: None; A. Lenert: None; A. Jones: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1; M. Danila: Boehringer-Ingelheim, 2, Pfizer, 5; B. England: Boehringer-Ingelheim, 2, 5; B. Sauer: None; J. Rojas: None; I. Smith: None.

To cite this abstract in AMA style:

Cannon G, Wallace B, Lazaro D, Schwab P, Monach P, Shah A, Kerr G, Reimold A, Baker J, Kunkel G, Wysham K, Caplan L, Richards J, Lenert A, Jones A, Mikuls T, Danila M, England B, Sauer B, Rojas J, Smith I. A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-multimodal-intervention-improves-the-quantity-and-quality-of-disease-activity-measures-collection-in-a-multi-centered-national-rheumatoid-arthritis-network/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multimodal-intervention-improves-the-quantity-and-quality-of-disease-activity-measures-collection-in-a-multi-centered-national-rheumatoid-arthritis-network/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology